Topical Tofacitinib in Treatment of Alopecia Areata

The document discussed the use of topical tofacitinib, a Janus kinase inhibitor, as a treatment for alopecia areata, an autoimmune disease causing non-scarring hair loss. Traditional treatments had low efficacy, especially in resistant cases. The study highlighted the potential of Janus kinase inhibitors to become a first-line treatment option in the future, either topically or orally. The case involved a 23-year-old female with a 12-year history of alopecia areata, illustrating the potential benefits of this new therapeutic approach.